Navigation Links
Cadence Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Date:11/11/2010

SAN DIEGO, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) today announced that it has priced an underwritten public offering of 11,500,000 shares of its common stock at a price to the public of $8.00 per share.  The net proceeds from the sale of the shares, after estimated underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $86.2 million.  The offering is expected to close on or about November 16, 2010, subject to customary closing conditions. Cadence has granted the underwriters for the offering an option for a period of 30 days to purchase up to an additional 1,725,000 shares of common stock to cover over-allotments, if any.

Deutsche Bank Securities Inc. is acting as sole book-running manager for the offering.  Leerink Swann LLC is acting as co-lead manager, and JMP Securities, Wedbush PacGrow Life Sciences and Canaccord Genuity Inc. are acting as co-managers for the offering.The securities described above are being offered by Cadence pursuant to shelf registration statements that have been previously filed with and become effective by rule or order of the Securities and Exchange Commission (the "SEC").  A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement relating to these securities, when available, may be obtained from Deutsche Bank Securities Inc., Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, Telephone number: (800) 503-4611, Email: prospectusrequest@list.db.com.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of t
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Reports Third Quarter 2010 Financial Results
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2010 Financial Results on November 5, 2010
3. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
4. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
5. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
6. Cadence Pharmaceuticals CEO Ted Schroeder To Present at the Oppenheimer 20th Annual Healthcare Conference in New York City on November 4, 2009
7. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
8. Cadence Pharmaceuticals to Webcast October 7th Analyst Day
9. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Sanofi (EURONEXT: ... REGN) today announced that the New England Journal ... study results of dupilumab (SAR231893/REGN668) in patients with moderate-to-severe ... the alpha subunit of the interleukin 4 receptor (IL-4R ... drivers of Th2 (Type 2 helper T cell) immune ...
(Date:5/21/2013)... -- U.S. spending on specialty prescription drugs — those ... multiple sclerosis and rheumatoid arthritis — is projected to ... to a forecast released today by Express Scripts (NASDAQ: ... "As we see what,s on the horizon, ... so they can continue to offer an affordable pharmacy ...
(Date:5/21/2013)... , May 21, 2013  AcelRx Pharmaceuticals, ... specialty pharmaceutical company focused on the development ... treatment of acute and breakthrough pain, today ... placebo-controlled Phase 3 study of its investigational ... (NanoTab System), the primary efficacy endpoint was ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10
... REDWOOD CITY, Calif., May 6, 2011 AcelRx Pharmaceuticals, ... company focused on the development and commercialization of innovative ... today announced that Richard King, President and Chief Executive ... Research Conference at the San Francisco Ritz Carlton. The ...
... MIAMI, May 6, 2011 SaveRxCanada.com the premier Canadian pharmacy ... still purchase Canada drugs from a Canada pharmacy ... Canada drugs can be 85% less than the U.S. ... clientele since 2002. 2. Convenience – Many patients are ...
Cached Medicine Technology:AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference 2Canadian Pharmacy Intermediary's Top Reasons U.S. Customers Choose Canada Online Pharmacies Revealed by SaveRxCanada.com 2
(Date:5/21/2013)... roles two proteins, thrombospondin-1 and prosaposin, play in ... identified a five-amino acid fragment of prosaposin that ... prostate, breast and lung cancer. The findings suggest ... in a variety of cancers. , The ... Boston Children,s Hospital, Vivek Mittal, PhD, at Weill ...
(Date:5/21/2013)... the removal of the adenoids and tonsils, is performed ... as a treatment for children with obstructive sleep apnea. ... attention and executive functioning, behavior, sleep apnea symptoms, and ... now. A study led by Susan Redline, MD, ... Cardiovascular Medicine and Associate Clinic Director of the Division ...
(Date:5/21/2013)... Harbor, Florida (PRWEB) May 21, 2013 ... agency, announced today that they have redesigned their website ... a nude beach, pool, hot tubs, bars and dining. ... this nudist resort including sales and guest reviews, will ... island of Jamaica itself, including pages on culinary local ...
(Date:5/21/2013)... The American Diabetes Association ( http://goo.gl/YRSF1 ... United States of America are affected with peripheral neuropathy. ... risk of developing peripheral neuropathy which unfortunately makes it ... further goes on saying that the disease usually affects ... million new cases are diagnosed every year in the ...
(Date:5/21/2013)... Aggressive treatment for prostate cancer may not be ... conditions, a new study finds. Treatments for ... seed implants, can cause serious side effects, such ... explained researchers from the University of California, Los ... patients with slower growing forms of prostate cancer ...
Breaking Medicine News(10 mins):Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:Age, Other Illnesses May Make Prostate Cancer Treatment Unnecessary 2
... Two Chinese soybean lines that grow without the primary ... have been isolated by scientists//. ,The two lines ... given away to breeders seeking to produce new varieties ... scientists at the University of Illinois at Urbana-Champaign and ...
... into action by mutations of the virus into a human flu ... what plan of action can we rely on to control the ... countries are teaming up next month to roll out a mock ... a pandemic. ,Australia and Singapore will be co-coordinating the ...
... of the out of hours health care system in England as ... ,The public accounts committee claimed that the new health care ... many key targets. ,In 2004 most GPs had opted ... PCTs took over in 90% of cases. ,The NAO ...
... plans for slow suffocation of millions of poultry, in ... ,According to Compassion in World Farming (CIWF) ... have been amended under emergency procedures whereby the Secretary ... a method of culling poultry in the event of ...
... a type 1 diabetic has been reported missing in West ... of medication// leaving her gravely ill, police have appealed for ... home in Uphall, at 2 pm on Monday. Stephanie went ... in Livingston. She is white, 5 ft 2in, of stocky ...
... University in Scotland found that women with high levels ... following in vitro fertilization. They found that the supplement ... after fertility treatment. ,However, the researchers said ... birth defects such as spina bifida, does not affect ...
Cached Medicine News:Health News:Promise for Soya Allergy Sufferers 2Health News:High Levels Of Folic Acid May Increase The Chances Of Twins After IVF 2
The Foundation PS knee offers a femoral option and tibial insert which provides a specially designed cam action that engages at 60 degrees of flexion to induce a smooth stable femoral roll-back motio...
... Natural Knee design includes several ... CSTi porous coating option for ... a unique bone preserving posterior ... groove to maximize range of ...
... Total Knee System provides anatomical replacement of ... while preserving the stabilizing Anterior and Posterior ... motion of the knee. All the components ... sizes and are equally proportioned and contoured ...
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i...
Medicine Products: